TheraRadar
Home/Indications/Oncology/Non-Hodgkin Lymphoma

Non-Hodgkin Lymphoma

Oncology 1 original drugs
1
Novel Drugs
6
Reformulations
1,640
Active Trials
5
Drug Targets

Oncology indication. Non-Hodgkin Lymphoma has 1 FDA-approved novel treatment, led by SHORLA, with 1640 active industry clinical trials across 5 drug targets. Explore market leaders, treatments by mechanism, the clinical pipeline, and drug targets below.

Non-Hodgkin Lymphoma Market Leaders

Companies with the most FDA-approved novel Non-Hodgkin Lymphoma drugs.

#1
SHORLA
1
original drugs

Phase 3 Readouts Pro

12 active Phase 3 trials with confidence-graded completion dates.

Full calendar →
Q4 2026
Ibrutinib
Johnson & Johnson
Estimated · fresh NCT01804686
Q1 2027
zanubrutinib
BeOne Medicines
Estimated · aging NCT04002297
Q2 2027
Odronextamab
Regeneron
Estimated · fresh NCT06230224
Unlock 9 more readouts with confidence-graded estimates
Upgrade to Pro

Anchored on CT.gov primary completion date. Topline announcements typically precede this by 3–9 months. Confidence labels combine date type (ACTUAL/ESTIMATED) with last-update freshness.

Non-Hodgkin Lymphoma Treatments by Mechanism

Top 12 mechanisms across 59 industry trials with a known mechanism of action.

See full pipeline →
Kinase Inhibitor
22 trials 5 active 8 sponsors
DNA
5 trials 2 active 3 sponsors
CD19
10 trials 1 active 2 sponsors
CD20-directed Cytolytic Antibody
4 trials 1 active 2 sponsors
Thalidomide Analog
4 trials 2 sponsors
Programmed Death Receptor-1 Blocking Antibody
4 trials 2 sponsors
PI3K-delta/PI3K-gamma
3 trials 2 sponsors
CD30-directed Immunoconjugate
2 trials 1 sponsor
CD19/CD3
2 trials 1 sponsor
AKT1/AKT2/AKT3
1 trials 1 sponsor
Proteasome Inhibitor
1 trials 1 sponsor
BCL-2 Inhibitor
1 trials 1 sponsor

MoA derived from FDA pharmClassEpc when intervention matches an approved drug. Codenamed clinical-stage assets without an approved counterpart show "—" and aren't grouped here — they're still in the phase tables below.

Non-Hodgkin Lymphoma Clinical Pipeline by Phase

410 industry-sponsored trials across 209 sponsors

View full landscape →

Novel Non-Hodgkin Lymphoma Drugs by Company (New molecular entities)

1 company has an FDA-approved novel drug for Non-Hodgkin Lymphoma.

SHORLA 1 drug
JYLAMVO
METHOTREXATE
NDA 2022
Reformulations (6 drugs) Click to expand

Reformulations are FDA-approved versions of existing molecules in new dosage forms (e.g., oral solution vs tablet, extended-release vs immediate-release). They require a new NDA but use an already-proven active ingredient.

VIVIMUSTA
AZURITY
T5 2022
BELRAPZO
EAGLE PHARMS
T5 2018
BENDEKA
EAGLE PHARMS
T5 2015
ZYDELIG
Gilead Sciences
T9 2014
TREANDA
CEPHALON
T1 2008
DOXIL (LIPOSOMAL)
Baxter
T3 1995

Non-Hodgkin Lymphoma Drug Targets

Molecular targets of approved and investigational Non-Hodgkin Lymphoma drugs — 5 targets tracked.

Dihydrofolate reductase 3 PI3Kδ 2 DNA 2 RNA 2 Topoisomerase II 2
Generic Drugs (4 ANDA approved) Click to expand

Generic drugs contain the same active ingredient as the brand-name drug and are approved via ANDA (Abbreviated New Drug Application).

DOXORUBICIN HYDROCHLORIDE (LIPOSOMAL)
Sun Pharma
IDELALISIB
NATCO
METHOTREXATE SODIUM PRESERVATIVE FREE
CAPLIN ONE LABS
TREXALL
Teva

Related Indications

Other Oncology indications

View all Oncology

Drug Categories:

  • Novel Drugs: NDA Type 1/2 (new molecular entity) or original BLA
  • Reformulations: NDA Type 3/5 (new dosage form of existing molecule)
  • Biosimilars: BLA-approved biologics highly similar to reference products
  • Generics: ANDA-approved copies of small molecule drugs

View data sources and methodology